Strong domestic growth drove results: Second-quarter product sales rose 11.5% year over year to $7.2 million, while net income increased to $1.8 million from $500,000. Domestic sales grew 27.7%, offsetting a 38.9% decline in international sales. First Defense continued gaining market share: First-half Tri-Shield sales grew 25.1%, while distributor volumes increased 24%.
First Defense's share of U.S. animals treated with biological scours preventatives rose to about 19% by June, from 15% in December 2025. Capacity expansion is planned through 2027: ImmuCell expects to invest approximately $8 million in freeze-drying and liquids-processing upgrades that should more than triple manufacturing capacity and reduce processing times. Near-term margins were pressured by lower production output, scrap costs and recurring expenses tied to the discontinued Re-Tain program.
ImmuCell (NASDAQ:ICCC) reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027. Product sales rose 11.5% year over year to $7.2 million in the second quarter of 2026. For the first six months of the year, product sales increased 20.9% to $17.5 million, according to Chief Financial Officer Timothy C.
Fiori. → Lumentum Just Delivered the AI Growth Investors Wanted The company recorded second-quarter net income of $1.8 million, or $0.20 per share, compared with net income of $500,000, or $0.06 per share, a year earlier. Results included a previously announced $2 million settlement with ImmuCell's former Re-Tain contract manufacturer. First-half net income totaled $3.8 million, compared with $1.9 million in the prior-year period.
Domestic second-quarter sales increased 27.7% to $6.2 million, while international sales declined 38.9% to about $1 million. Fiori said the international decrease was primarily attributable to sales in Canada, where prior-year results benefited from orders associated with clearing a backorder situation. → AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be President and CEO Olivier te Boekhorst said the company's strategic focus since late 2025 has been on its First Defense calf scours preventative portfolio. Tri-Shield, the company's flagship product, posted 25.1% growth during the first half of 2026, he said.
The company's Functional Feed line contributed approximately 20% of overall first-half growth. U.S. sales grew 32.5% in the first half compared with the same period in 2025. → Joby's Defense Pivot Accelerates With $500M Resonant Sciences Deal ImmuCell said distributor out-the-door volumes, which it uses as an indicator of sales at the producer level, increased 21% in the first quarter and 28% in the second quarter, producing first-half volume growth of 24% year over year. The company estimated that First Defense's share of U.S. animals treated with a biological scours preventative increased from about 15% in December 2025 to about 19% at the end of June.
Extract — continue reading at the source.
